文献速递骨软组织肉瘤与黑色素瘤

Intismeran联合帕博利珠单抗对比帕博利珠单抗单药治疗高危切除黑色素瘤:KEYNOTE-942随机IIb期研究5年更新

Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study.
PubMed 文献 · J Clin Oncol · 2026-06-01

KEYNOTE-942研究5年更新显示,在157例切除的IIIB-IV期皮肤黑色素瘤患者中,intismeran联合帕博利珠单抗对比帕博利珠单抗单药继续延长无复发生存(HR 0.510)和无远处转移生存(HR 0.411),总生存有有利趋势(HR 0.471),安全性可控且无新信号。

要点

  • 联合组5年RFS HR 0.510,DMFS HR 0.411,均优于单药。
  • OS HR 0.471但95%CI宽,为有利趋势。
  • 安全性可控,无新安全信号。

核心结论

  • intismeran联合帕博利珠单抗在切除高危黑色素瘤中显示持续、持久的治疗获益。

研究设计与样本

  • IIb期KEYNOTE-942研究随机2:1分配,157例切除的IIIB-IV期皮肤黑色素瘤患者接受intismeran联合帕博利珠单抗(n=107)或帕博利珠单抗单药(n=50)。

主要发现

  • 中位计划随访60.3个月(范围50.5-76.4),联合组对比单药的RFS HR为0.510(95%CI 0.294-0.887)。
  • DMFS HR为0.411(95%CI 0.200-0.843),OS HR为0.471(95%CI 0.165-1.345)。
  • 联合组T细胞受体克隆性增加及新克隆型出现,无复发患者中新克隆扩增更明显。

临床怎么用

  • 对于切除的IIIB-IV期皮肤黑色素瘤高危患者,intismeran联合帕博利珠单抗可作为潜在治疗选择,需结合个体情况评估。

局限性

  • 5年分析为描述性,样本量较小(共157例),OS置信区间宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intismeran autogene (intismeran; formerly V940 or mRNA-4157) is an mRNA-based individualized neoantigen therapy. We report 5-year outcomes of intismeran plus pembrolizumab from the phase IIb KEYNOTE-942 study (ClinicalTrials.gov identifier: NCT03897881). Eligible patients with resected stage IIIB to IV cutaneous melanoma were randomly assigned 2:1 to receive nine doses of intramuscular intismeran 1 mg once every 3 weeks plus 18 doses of intravenous pembrolizumab 200 mg once every 3 weeks or 18 doses of intravenous pembrolizumab 200 mg once every 3 weeks. The primary end point was recurrence-free survival (RFS); secondary end points included distant metastasis-free survival (DMFS) and safety. Five-year analyses were descriptive. Among 157 randomly assigned patients (intismeran plus pembrolizumab, n = 107; pembrolizumab, n = 50), the median planned follow-up at data cutoff (December 15, 2025) was 60.3 (range, 50.5-76.4) months. Intismeran plus pembrolizumab continued to prolong RFS (hazard ratio [HR], 0.510 [95% CI, 0.294 to 0.887) and DMFS (HR, 0.411 [95% CI, 0.200 to 0.843]), with a favorable trend in overall survival (HR, 0.471 [95% CI, 0.165 to 1.345]) versus pembrolizumab. Safety profile continued to be manageable, with no new safety signals. Intismeran plus pembrolizumab was associated with increased T-cell receptor clonality and novel clonotypes versus pembrolizumab; greater novel clone expansion was observed in patients without versus with recurrence in the combination arm. After a 5-year follow-up, intismeran plus pembrolizumab demonstrated sustained, durable treatment benefits versus pembrolizumab alone in resected high-risk melanoma.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Khattak A, Carlino MS, Meniawy T, et al. Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study. J Clin Oncol. 2026. PMID: 42223134. doi:10.1200/JCO-26-00835

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。